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Summary  Bacterial  resistance  to  antimicrobial  agents  is  increasing.  Complex  resis-
tant  mechanisms  have  resulted  in  a  wide  spectrum  of  species  and  strains  with
multidrug-resistant  patterns.  In  addition  to  the  production  of  extended-spectrum-
-lactamases  (ESBLs),  Gram-negative  rods  have  acquired  the  capacity  to  hydrolyze
carbapenem  antibiotics  by  means  of  carbapenemases.  The  enzyme  that  has  gained
the  most  publicity  recently  is  the  New  Delhi  metallo--lactamase  (NDM-1).  This
enzyme  and  others  are  now  spreading  from  their  homeland  on  the  Indian  subconti-
nent  to  other  continents,  primarily  via  medical  tourists.  This  spread  contributes  to
be  a  global  threat  in  an  era  when  no  potent  antibiotics  are  expected  to  be  devel-
oped.  Patients  coming  from  countries  where  antimicrobial  use  is  not  restricted,  such
as  Iraq,  may  harbor  similar  organisms.  Reports  from  the  Middle  East  and  Arabian
countries  describing  the  occurrence  of  carbapenem-resistant  Enterobacteriaceae
are  rare.  In  this  communication,  an  update  on  the  epidemiology,  prevalence  and
mechanisms  of  carbapenem-resistant  Enterobacteriaceae  in  Lebanon  and  the  sur-
rounding  region  will  be  addressed  in  addition  to  the  detection  methods  and  required
infection  control  practices.
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mechanisms  of  resistance  among  Gram-negative
Enterobacteriaceae  vary  widely  [1].  The  emer-
gence  of  extended-spectrum--lactamases  (ESBLs)
compromised  the  effect  of  most  -lactam  antibi-
otics [2].  In  this  situation,  carbapenem  antibiotics
remain  the  drug  of  choice  and  have  been
increasingly  utilized  to  treat  infections  with  ESBL-
producing  organisms  [3].  However,  the  increasing
rates of  ESBLs  isolates  are  leading  to  the  overuse
of carbapenems,  creating  antibiotic  pressure  on
carbapenems  and  triggering  bacterial  resistance
against this  class  of  antimicrobial  agents.  Subse-
quently,  carbapenemases  have  been  increasingly
detected among  Enterobacteriaceae,  limiting  the
existing antimicrobial  armamentarium  for  treating
these resistant  isolates  [4].
Reports of  carbapenem-resistant  Enterobacteri-
aceae have  been  published  from  different  regions,
including  Europe,  North  America  and  Latin  Amer-
ica [5].  Reports  from  Lebanon  are  scarce  [6,7].  In
addition,  no  publications  are  available  describing
the  emergence  of  such  strains  from  neighboring
countries aside  from  Turkey,  Israel,  Oman  [8]  and
Kuwait [9].  Devastating  new  carbapenemases,  par-
ticularly NDM-1,  have  recently  been  reported  from
the Indian  subcontinent  and  subsequently  spread
to other  countries.  The  above-mentioned  complex-
ities  and  alarming  threats  warranted  this  update  to
shed light  on  the  carbapenemases  challenging  clin-
ical and  laboratory  settings  and  the  treatment  of
the bacterial  infections  producing  these  enzymes.
In addition,  a  description  of  the  global  and  local
epidemiology  is  provided.
Carbapenemases and mechanisms of
resistance
The  carbapenem  antibiotic  family  includes  bia-
penem, doripenem,  ertapenem,  faropenem  (a
closely related  penem  to  carbapenems),  imipenem,
meropenem,  panipenem,  thienamycin  and  razu-
penem.  These  penems  originally  developed  from
thienamycin,  a  natural,  fungal-derived  product  of
Streptomyces  cattleya  [10].  The  bactericidal  activ-
ity of  carbapenems  results  from  the  inhibition  of
cell wall  synthesis.  Because  of  their  zwitterionic
molecule charges,  carbapenems  readily  penetrate
the  cell  wall  of  most  Gram-positive  and  Gram-
negative bacteria  to  reach  and  act  on  targets
pertaining to  penicillin-binding  proteins  (PBPs  1A,
1B, 2,  3,  4,  5,  6).
Several  mechanisms  account  for  the  resis-
tance to  carbapenems;  these  include  modiﬁcations
in the  target  substrate  PBP,  outer  membrane
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ermeability  modiﬁcations,  and  the  production
f ESBLs  and  other  hydrolyzing  enzymes.  The
atter  existed  years  before  the  license  of  car-
apenem antibiotics  for  use  in  the  USA  and  United
ingdom  [4].  Hydrolyzing  enzymes  occur  natu-
ally in  some  Gram-negative  bacteria,  such  as
tenotrophomonas  maltophilia, Flavobacterium,
hryseobacterium  spp.  and  Aeromonas  hydrophila.
arbapenem-resistance  among  Enterobacteriaceae
acteria is  primarily  associated  with  the  pro-
uction of  carbapenemases.  Dual  mechanisms,
ncluding an  outer  membrane  permeability  defect
ith the  production  of  -lactamases,  such  as  AmpC
ephalosporinases  and  ESBLs,  particularly  with  the
resence of  the  CTX-M  variant,  have  also  been
escribed [11].
lassiﬁcation
here  are  various  classiﬁcations  of  carbapenemases
n use.  The  most  commonly  used  is  the  Ambler
lassiﬁcation, which  classiﬁes  the  carbapenemases
nto three  classes,  A,  B,  and  D,  depending  on  the
mino acid  sequence  homology.  Classes  A  and  D
re serine  carbapenemases,  while  class  B contains
etallo--lactamases  (MBL)  [12].  An  update  on  the
mbler classiﬁcation  of  carbapenemase  classes  is
resented in  Table  1.  The  carbapenemase  genes
re located  on  highly  mobile  genetic  elements  that
ontribute  to  their  rapid  spread  and  frequent  trans-
er of  multiple  other  antibiotic  resistance  genes.  A
rief description  of  these  classes  follows.
Class A  carbapenemases  were  ﬁrst  detected
n 1982.  They  include  the  following  enzymes:
PC (Klebsiella  pneumoniae  carbapenemase),  SME
Serratia marsescens  enzyme),  NMC-A  (not  metal-
oenzyme  carbapenemase  class  A),  IMI  (imipenem-
ydrolyzing) and  GES  (Guiana  extended-spectrum),
ach of  which  have  different  family  mem-
ers. These  enzymes  hydrolyze  all  -lactams
ncluding monobactams,  have  a high  afﬁnity
or meropenem  and  hold  less  hydrolytic  activ-
ty towards  cephamycins  and  ceftazidime.  This
lass can  carry  resistance  to  ﬂuoroquinolones  and
minoglycosides  because  the  encoding  genes  for
uinolone  and  aminoglycoside  resistance  are  car-
ied on  the  same  plasmids.  They  are  inhibited
y clavulanic  acid  and  tazobactam  but  not  sul-
actam.  They  are  found  in  Enterobacteriaceae
e.g.,  Klebsiella  pneumoniae,  Klebsiella  oxytoca,
almonella  enterica,  Citrobacter  freundii,  Enter-
bacter  aerogenes,  Enterobacter  cloacae  and
erratia  marcescens) and  non-Enterobacteriaceae
e.g.,  Pseudomonas  aeruginosa  and  Acinetobacte
pp.). The  KPC  enzyme  is  the  most  clinically
mportant in  this  group  and  was  discovered  in
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Table  1  Classes  of  carbapenemases  according  to  Ambler  classiﬁcation.
Ambler  class  Example  of
enzymes
Inhibition  Antimicrobial  hydrolysis  properties  Bacterial
example
Yes  No
A KPC,  IMI,  SME,
GES  NMC-A
Clavulanic
acid
Tazobactam
All  -lactams
Carbapenems
Monobactam
Ceftazidime
Cephamycin
Klebsiella
pneumoniae
Escherichia  coli
Enterobacter
cloacae
Pseudomonas
aeruginosa
Serratia  spp.
Salmonella
enterica
Citrobacter
freundii
B  metallo--
lactamses
IMP,  VIM,  GIM,
SPM
NDM-1,  SIM
EDTA  All  -lactams
Carbapenems
Aztreonam  Pseudomonas
aeruginosa
Klebsiella
pneumoniae
Escherichia  coli
Acinetobacter
spp.
Citrobacter
freundii
Serratia
marcescens
Morganella
morganii
Providencia
spp.
D  oxacillinase  OXA-48  In  vitro  by
NaCl
Penicillins
Carbapenems
Cephalosporins
Aztreonam
Extended-
spectrum-
cephalosporins
Acinetobacter
spp.
Proteus
mirabilis
Pseudomonas
aeruginosa
Klebsiella
pneumoniae
Escherichia  coli
C  AmpC
CMY  +  mutation  in
OMP
Clavulanic
acid
Sulbactam
Tazobactam
Penicillins
Cephamycin
Oxyiminocephalosporin
Azteonam
bape
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996  in  North  Carolina.  The  encoding  gene  blaKPC
s  plasmid  mediated  with  nine  different  variants
4,13,14]. These  enzymes  have  been  reported  in
any countries,  including  Israel,  India,  France,
ortugal,  Holland,  Greece,  Japan,  China,  Korea,
razil,  Colombia,  Argentina  and  the  USA  [4].
Class B  carbapenemases  are  metallo--actamases (MBL)  and  the  most  clinically
igniﬁcant carbapenemases.  Enzymes  in  this
lass include  IMP  (active  on  imipenem),  VIM
T
(
tnem
Verona  integron-encoded  metallo--lactamase),
IM (German  imipenemase),  SPM  (Sao  Paulo
etallo--lactamase) and  SIM  (Seoul  imipene-
ase). IMP-1  was  the  ﬁrst  metallo--lactamase
dentiﬁed  in  Japan  in  1991  from  a  Serratia
arcescens  isolate.  These  enzymes  hydrolyze  all
-lactams and  carbapenems  but  not  aztreonam.
hey are  inhibited  by  ethylenediaminetetraacetic
EDTA), a metal  ion  chelator,  and  resistant  to  all  of
he commercially  available  -lactamase  inhibitors.
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Table  2  Summary  of  different  carbapenemases  recovered  in  different  countries  neighbouring  Lebanon.  +  indicates
present  and  the  number  next  to  each  +  indicates  the  subtypes  of  the  different  enzymes.  OXA  included  subtypes
1,47,48;  VIM  included  subtypes  1,2,4,5,12,19;  KPC  included  subtypes  2  and  3.
Country  Types  of  detected  carbapenemase
Author/year OXA  VIM  KPC  NDM-1
Lebanon
Matar  et  al./2008  48
Matar  et  al./2010  48
El-Herte  et  al./2012  48  +
Turkey
Poirel  et  al./2004 +1,47,48
Gac¸ar  et  al./2005  5
Aktas¸  et  al./2008  48
Gülmez  et  al./2008  48
Carrer  et  al./2008  48
Carrer  et  al./2010  48
Egypt
Cuzon  et  al./2009  48
Kuwait
Jamal  et  al./2011  +
Oman
Poirel  et  al./2010  +
Saudi  Arabia
Guerin  et  al./2005  48
Israel
Navon-Venezia  et  al./2006  2
Leavitt  et  al./2007  3
Lopez  et  al./2010 3
Greece
Giakkoupi  et  al./2003 1
Loli  et  al./2006 1
Ikonomidis  et  al./2007 4
Ikonomidis  et  al./2007 +1/+2
12
Psichogiou  et  al./2008 1
Tsakris  et  al./2008 2
Tokatlidou  et  al./2008 12
Giakkoupi  et  al./2009  1  2
Giakkoupi  et  al./209  2
Pournaras  et  al./2009  2
Hawser  et  al./2009  KPC  not  subtyped
Pournaras  et  al./2010  19  2
Kontopoulou  et  al./2010  2
h
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2Zioga  et  al./2010  
The  genes  responsible  for  this  are  chromosomal  or
plasmid-encoded  and  naturally  present  in  Bacillus
cereus,  Aeromonas  spp.  and  Stenotrophomonas
maltophilia  [13,15—24]. They  have  also  been  found
in several  Gram-negative  bacteria,  such  as  Enter-
obacteriaceae, Pseudomonas  aeruginosa, Brevium
diminuta,  Pseudomonas  ﬂuorescens,  Burkholderia
cepacia, Achromobacter  (Alcaligenes) xylosoxy-
dans,  Pseudomonas  putida  and  Acinetobacter
baumannii  [13,14].  Reports  on  these  enzymes
m
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[1  2
ave been  noted  from  different  countries  around
he world,  including  some  from  our  region  (e.g.,
reece  and  Turkey)  [13].  In  2008,  a  new  metallo-
-lactamase, NDM-1,  was  identiﬁed  in  a  Swedish
atient previously  hospitalized  in  India  [25].  As  of
009, NDM-1  had  spread  from  India  and  Pakistan  via
edical tourists  to  the  UK,  USA,  France,  Germany,
ustralia and  other  countries  [26].  In  the  Gulf
egion, NDM-1  was  ﬁrst  reported  in  Oman  [8],  Iraq
27] and,  more  recently,  Kuwait  [9]  and  Lebanon
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ahe  threat  of  carbapenem-resistant  Enterobacteria
28].  The  bacteria  carrying  this  enzyme  are  Kleb-
iella pneumoniae, Escherichia  coli,  Citrobacter
reundii, Enterobacter  cloacae,  Providencia  spp.
nd Morganella  morganii.  These  bacteria  were  pri-
arily recovered  from  community-acquired  urinary
ract infections,  pneumonia,  and  blood  stream
nfections [26].  Bacteria  producing  this  enzyme
ydrolyze all  -lactam  antibiotics  and  are  usually
esistant to  other  classes  of  antibiotics;  thus  far,
hese bacteria  only  remain  susceptible  to  colistin
nd tigecycline.  The  blaNDM-1 gene  encoding  this
nzyme has  been  located  on  a  plasmid  and  chro-
osomes  in  three  UK  isolates,  suggesting  in  situ
ovement  [29].  The  isolates  were  from  different
lones, except  for  the  ones  recovered  in  Haryana,
ndia, which  were  monoclonal  [29].  The  bacteria
roducing MBLs,  especially  NDM-1,  represent  a
reat burden  because  of  their  potential  for  rapid
pread  throughout  the  continents  and  because
hey often  harbor  genes  encoding  for  resistance  to
ther classes  of  antibiotics  on  the  same  plasmid
quinolones and  aminoglycosides)  in  an  era  in
hich few  new  potent  antimicrobial  agents  active
gainst  carbapenem-resistant  organisms  are  on  the
orizon.
Class D  carbapenemases  are  also  called  oxacillin-
ydrolyzing -lactamases  (OXAs)  [13].  The  enzyme
as ﬁrst  puriﬁed  from  a  multidrug-resistant  Acine-
obacter  baumannii  strain  isolated  in  1985  from
 patient  in  Scotland  and  ﬁrst  described  in  1993
30]. Its  spectrum  of  hydrolysis  covers  penicillin,
mipenem and  meropenem  but  not  the  extended-
pectrum cephalosporins  and  aztreonam.  Their
ctivity  is  poorly  inhibited  by  clavulanic  acid  but
s inhibited  at  variable  levels  by  sodium  chloride
n vitro.  In  isolation,  the  enzyme  was  designated
RI-1 (for  Acinetobacter  resistant  to  imipenem)  but
as later  labeled  OXA-23.  Most  of  the  OXA-type
arbapenemase  genes  appear  to  be  chromosoma-
ly located  in  Acinetobacter  spp.,  Pseudomonas
eruginosa, Shewanella  oneidensis,  Shewanella
lgae, Ralstonia  pickettii,  and  other  rare  Enter-
bacteriaceae.  Unfortunately,  this  enzyme  was  also
ecovered from  some  isolates  of  K.  pneumoniae,
. coli  and  Proteus  spp.  Currently,  121  different
ariants of  class  D  -lactamases  have  been  iden-
iﬁed  on  the  protein  level,  and  45  of  these,  namely
he OXA-48  enzyme  encoded  by  the  blaOXA-48
ene,  exhibit  carbapenem-hydrolyzing  activities.
his enzyme  was  reported  in  different  countries
round the  world,  including  those  from  our  region
e.g., Turkey,  Egypt,  Saudi  Arabia  and  Lebanon)
6,7,13,14,30,31].
The other  mechanisms  by  which  Enterobac-
eriaceae  are  resistant  to  carbapenems  are  the
xpression  of  AmpC  and  an  altered  outer  membrane
b
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rotein  (OMP)  that  causes  decreased  perme-
bility to  carbapenems;  these  strains  usually
emain susceptible  to  cefepime  and  imipenem  but
ay become  ertapenem  resistant.  AmpC,  which
elongs  to  class  C  -lactamases,  was  described
n 2006,  when  it  was  isolated  from  a viru-
ent strain  of  Enterobacter  aerogenes. These
trains are  resistant  to  penicillins,  cephalosporins,
ephamycins,  oxyiminocephalosporins,  ertapenem
nd aztreonam  but  not  to  cefepime.  The  gene
s plasmid  mediated  and  often  carries  multiple
ther genes  for  resistance  to  aminoglycosides,
hloramphenicol,  quinolones,  sulfonamide,  tetra-
ycline and  trimethoprim,  as  well  as  genes
or other  -lactamases.  Benzylpenicillin,  ampi-
illin,  amoxicillin  and  cephalosporins  (cefazolin
nd cephalothin)  are  strong  inducers  and  good
ubstrates  for  AmpC  -lactamase.  Cefoxitin  and
mipenem  are  also  strong  inducers  but  are
uch more  stable  for  hydrolysis.  Cefotaxime,
eftriaxone,  ceftazidime,  cefepime,  cefuroxime,
iperacillin and  aztreonam  are  weak  inducers  and
eak substrates  but  can  be  hydrolyzed  if  enough
nzymes are  produced.  Consequently,  the  MICs
f weakly  inducing  oxyimino--lactams  are  dra-
atically  increased  with  AmpC  hyperproduction.
lavulanic  acid,  sulbactam,  and  tazobactam  have
uch less  effect  on  AmpC  -lactamases,  although
ome are  inhibited  by  tazobactam  or  sulbactam.
Thus, organisms  producing  enough  AmpC  -
actamase  will  typically  have  a positive  ESBL
creening test  but  fail  the  conﬁrmatory  test  involv-
ng increased  sensitivity  with  clavulanic  acid.  The
ulprit enzyme  is  CMY  (cephamycin  hydrolyzing)
32]. The  development  of  resistance  upon  therapy
s a  major  concern;  an  accompanying  loss  of  outer
embrane  porins  can  further  augment  the  resis-
ance phenotype.  The  gold  standard  for  conﬁrming
heir presence  is  using  polymerase  chain  reactions
33]. Table  1  summarizes  the  different  classes  of
arbapenemases.
arbapenemases producing
nterobacteriaceae reported from Lebanon
nd neighboring countries
eports  on  the  presence  of  carbapenem-resistant
nterobacteriaceae  in  the  region  are  limited  to
 few  countries:  Lebanon,  Turkey,  Greece,  Israel,
gypt,  Kuwait  and  Saudi  Arabia.  Most  of  the  reports
re from  Turkey,  Greece  and  Israel.
In  Lebanon,  OXA-48  (class  D)  was  the  ﬁrst  car-
apenemase  reported,  in  2008,  followed  by  another
eport in  2010;  both  were  produced  by  E. coli  and
. pneumoniae. Genetic  studies  did  not  reveal  any
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genomic  relatedness  between  the  Lebanese  and
Turkish strains  harboring  the  plasmid  encoding  the
OXA-48 gene,  indicating  that  the  dissemination  of
carbapenem  resistance  is  not  clonal  but  through
horizontal plasmid  transfer  [6,7].  In  2009,  a study
from Lebanon  revealed  that  2.5%  of  E.  coli  and
7.84% of  K.  pneumoniae  were  ESBL  producers  and
carbapenem  resistant  [antimicrobial  brochure  at
the American  University  of  Beirut  Medical  Center
(AUB-MC)].  Most  recently,  E.  coli  and  K.  pneu-
moniae with  NDM-1  were  recovered  from  Iraqi
patients referred  for  treatment  in  France  [27]
and in  Lebanon  [28].  A  summary  of  the  differ-
ent carbapenemases  recovered  from  patients  in
Lebanon  and  its  neighboring  countries  is  presented
in Table  2.
In Turkey,  the  earliest  report  on  carbapenemases
was published  in  2001  and  described  class  D  OXA-48.
Subsequently,  many  reports  were  published  about
VIM (VIM-5)  and  IMP  recovered  from  different  Enter-
obacteriaceae  that  were  not  genetically  related  to
the strains  recovered  in  Lebanon  [15—18,34—36]. In
Greece, several  reports  have  been  published  about
encountered  carbapenemases.  They  were  class  A
KPC-2 and  class  B  VIM  types  1,  2,  4,  12  and  19
and recovered  from  different  Enterobacteriaceae
[19—24,37—41]. Reports  from  Israel  have  described
the detection  of  different  Enterobacteriaceae  pro-
ducing class  A  KPC  subtype-2  and  -3  since  2004
[42—46].  The  spread  of  a  KPC-3  producing  K.  pneu-
monia  from  Israel  to  Colombia,  the  UK,  Norway,
Sweden and  the  USA  via  medical  tourists  has  also
recently  been  reported  [46].
Although the  various  countries  discussed  share
regional  proximity,  it  is  interesting  to  note  the
differences  in  the  recovered  carbapenemases.  For
example,  similarities  in  the  KPC  enzymes  were
noted between  Israel  and  Greece,  and  similarities
between the  OXA  enzymes  were  noted  between
Turkey and  Lebanon.  These  similarities  may  be
attributed  to  interactions  between  different  pop-
ulations  and  communities  in  these  countries;  the
exact factors  that  promote  such  differences  remain
to be  identiﬁed.
The recovery  of  these  isolates  from  Egypt  was
noted in  only  one  report,  which  described  K.  pneu-
moniae  producing  class  D  OXA-48  in  an  Egyptian
patient hospitalized  in  France  [47].
There  is  only  one  report  from  Saudi  Arabia
of Pseudomonas  aeruginosa  harboring  the  blaVIM-2
from  a  Saudi  patient  hospitalized  in  France  [48].
Recently,  Poirel  et  al.  reported  a  transfer  of
NDM-1 from  Iraq  to  France  through  an  Iraqi
medical tourist  [26].  Moreover,  infection  with  NDM-
1-producing  K.  pneumoniae  has  also  been  reported
very recently  in  Kuwait  [9].
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Thus  far,  no  reports  of  carbapenem-resistant
nterobacteriaceae  have  been  published  from  Iran,
ordan, or  Syria.  Table  2  summarizes  the  enzymes
eported from  isolates  recovered  in  different  coun-
ries in  the  Middle  East.
etection
he  prompt  detection  of  carbapenemase-producing
acteria  is  of  paramount  importance,  as  it  has
n impact  on  both  appropriate  therapeutic  mea-
ures and  infection  control  practices.  Though
arbapenemase production  can  be  inferred  from
he resistance  proﬁle  of  the  isolate,  further  phe-
otypic  and  genotypic  tests  should  be  done  for
onﬁrmation.  A  carbapenem-resistant  Enterobac-
eriaceae  is  usually  suspected  when  resistance  to
rtapenem  or increased  MIC  (see  detail  in  the  com-
ng paragraph)  to  other  carbapenems  that  remains
ithin  the  susceptibility  range  is  observed.  For
xample,  in  one  study,  the  positive  predictive  value
nd speciﬁcity  of  ertapenem  resistance  for  KPC
etection  were  74%  and  99.2%,  respectively  [49].
his is  attributed  to  the  fact  that  resistance  to  car-
apenem can  be  due  to  the  presence  of  CTX-M,
SBLs and  porin  mutations  [49].  Deﬁnitive  iden-
iﬁcation,  however,  was  achieved  with  molecular
esting for  high  sensitivity  and  speciﬁcity  (100%  and
6.4%, respectively)  [50].
creening: disk diffusion and MIC
usceptibility testing
creening  begins  when  a strain  is  suspected  to  have
educed susceptibility  to  carbapenems  (decreased
nhibition zone  diameter  or  increased  MIC).  In  disk
iffusion susceptibility  testing,  a 10  g ertapenem
isk is  used  as  the  surrogate  marker  to  screen
or carbapenem  resistance  in  the  tested  isolates.
 zone  of  inhibition  or  mutant  detection  at  the
ntermediate  (16—18  mm)  or  resistant  (≤15  mm)
reakpoint  zones  should  be  analyzed  further  using
IC and  Hodge  testing.  The  strains  typically  indi-
ate high  MIC  (presented  below)  regardless  of  the
est used  (broth  dilution,  E test,  or  automated  sys-
em) and  can  vary  according  to  different  strains,
ut  the  MIC  is  usually  greater  than  that  of  the
orrespondent wild  type  of  the  bacteria.  A  false-
egative  result  can  be  due  to  a low  inoculum.  The
utomated  susceptibility  testing  instruments  have
ariable sensitivity,  ranging  from  7%  to  87%  [51,52].
 strain  is  considered  carbapenem  resistant  if
he following  breakpoints  are  found,  according
o the  CLSI  (updated  January  2011)  [53]:  in  disk
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Table  3  Summary  of  most  commonly  used  conﬁrmatory  methods  for  carbapenemases.  DPA  =  dipicolinic  acid;
MBL  =  metallo--lactamase;  EDTA  =  ethylenediaminetetraacetic  acid;  KPC  =  Klebsiella  pneumoniae  carbapenemase;
OXA  =  oxacillinase;  BA  =  boronic  acid;  CTX-M  =  cefotaximase.
Test  Sensitivity/speciﬁcity  Comments
Modiﬁed  Hodge  test 100%/78%  Cannot  differentiate  among  the  different
types  of  carbapenemases
Carbapenemases  inhibition 100%/98% DPA  inhibits  MBL
EDTA  inhibits  MBL,KPC,  OXA
BA  inhibits  KPC,  AmpC
False  positive  in  AmpC  plus  Omp,  CTX-M
Amino-acid  ampliﬁcation  100%/97%  Available  only  in  referral  centers  allows
differentiation  of  carbapenemases
Chromogenic  agar  media  100%/98%  Cannot  differentiate  among  the  different
classes  of  carbapenemases
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diffusion  testing  against  10  g  meropenem,  10  g
oripenem,  and  10  g  ertapenem;  a  zone  diame-
er ≤19  mm  (the  imipenem  disk  performs  poorly  as
 screen  for  carbapenemases);  and  in  MIC  testing
ith ≥4  mg/l  against  imipenem,  meropenem  and
oripenem,  and  MIC  ≥1  mg/l  against  ertapenem.
he use  of  ertapenem  as  the  surrogate  test  is  due  to
t being  the  least  active  carbapenem  against  KPCs,
nd the  use  of  this  drug  in  both  manual  and  auto-
ated  susceptible  testing  methods  has  been  found
o be  highly  sensitive  for  detecting  KPC  [49].
onﬁrmation
he  most  commonly  used  conﬁrmatory  tests  for
etecting  carbapenemases  are  the  modiﬁed  Hodge
est, carbapenemase  inhibition  tests  and  molecu-
ar methods  (Table  3)  [53,54].  Polymerase  chain
eaction  (PCR)  is the  most  reliable,  sensitive  and
peciﬁc test  for  detecting  carbapenemases.  PCR
ollowed by  spectrophotometric  measurements  of
arbapenem  hydrolysis  are  considered  to  be  the
eference  standard  methods  for  detecting  car-
apenemase  production  [50,55].
odiﬁed Hodge test
his  test,  also  known  as  the  cloverleaf  method,  is
ecommended  by  the  CLSI  to  phenotypically  detect
he presence  of  carbapenemases.  The  test  is  based
n the  growth  of  a  susceptible  strain  of  E.  coli
TCC 25922  around  the  area  of  the  resistant  strain
roducing  carbapenemases.  This  test  is  done  by
noculating  a  0.5  McFarland  dilution  of  E.  coli  ATCC
5922 on  a  Mueller  Hinton  agar  plate.  A  10  g
eropenem  or  10  g  ertapenem  susceptibility  disk
s placed  in  the  middle  of  the  inoculated  plate.  A
1
m
m
ietted  swab  with  the  suspected  test  organism  (0.5
cFarland) is  then  streaked  from  the  edge  of  the
isk to  the  edge  of  the  plate.  Up  to  four  organisms
an be  tested  on  the  same  plate  with  one  drug.
fter 16—24  h of  incubation,  the  plate  is  examined
or a cloverleaf-type  indentation  at  the  intersec-
ion of  the  test  organism  and  E.  coli  within  the  zone
f inhibition  of  the  carbapenem  susceptibility  disk.
he sensitivity  of  this  test  is  excellent  (95—100%),
ut it  cannot  differentiate  between  the  different
ypes of  carbapenemases  (speciﬁcity  =  78%)  [54].
he test  might  give  false-positive  results  if  the
train produces  ESBLs,  AmpC,  CTX-M  or  a weak  MBL
nd has  an  alteration  in  the  outer  membrane  pro-
ein [50,55,56].
arbapenemase inhibition test
his  test  is  based  on  the  enhanced  inhibition
one of  the  resistant  strain  when  carbapenemase
nhibitors are  inoculated  within  the  carbapenem
isk. There  are  many  carbapenemases  inhibitors;
he most  important  carbapenemases  inhibitors  are
ipicolinic acid  (DPA),  EDTA,  boronic  acid  (BA)
nd cloxacillin  [55].  The  DPA  inhibits  all  of  the
BL. The  EDTA  inhibits  the  MBL,  KPC,  CTX-M  and
he oxacillinases.  The  BA  will  inhibit  class  A  KPC,
lass C AmpC  and  CTX-M  ESBLs.  Various  studies
ave been  performed  regarding  this  method  with
arious  inhibitor  concentrations.  Optimal  results
re obtained  if  a Mueller—Hinton  agar  plate  is
treaked  with  a  0.5  McFarland  inoculum  of  the
ested  organism  followed  by  a 10  g  meropenem
isk, 10  g meropenem  disk  plus  1000  g  DPA  [55],
0 g  meropenem  disk  plus  750  g  EDTA,  10  g
eropenem disk  plus  600  g  APBA,  and  10  g
eropenem disk  plus  750  g cloxacillin  [57].  An
ncrease  ≥5  mm  in  the  inhibitory  zone  diameter
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around  the  carbapenem  disk  imbibed  with  the
inhibitor  conﬁrms  the  presence  of  carbapenemases.
A false-positive  result  might  be  obtained  if  the
strain has  an  OMP  modiﬁcation  and  produces  ESBL,
AmpC or  CTX-M.  The  sensitivity  and  speciﬁcity  are
100% and  98—100%,  respectively  [50,55—57].
Molecular methods
The  deﬁnitive  method  for  conﬁrming  the  type  of
carbapenemase  present  is  PCR  ampliﬁcation  and
sequence  analysis  of  extracted  DNA,  which  permits
the identiﬁcation  and  sequencing  of  the  differ-
ent encoding  genes,  e.g.,  pertaining  to  the  class
A enzymes  blaKPC, blaIMI,  blaNMC,  and  blaGES [12];
metallo--lactamases  (MBLs)  blaVIM,  blaIMP, blaGIM,
blaSPM,  blaSIM [12]  and  blaNDM; and  class  D OXA-
type carbapenemases  blaOXA-23 and  blaOXA-48 [12],
with the  sensitivity  and  speciﬁcity  of  these  meth-
ods reaching  100%  and  97%,  respectively  [58,59].
Though  these  tests  are  only  available  in  research
and referral  centers,  some  clinical  labs  are  turn-
ing to  PCR  ampliﬁcation  as  a  means  of  detection  to
overcome  problems  faced  with  phenotypic  bench
tests [50].  Other  genes  for  antimicrobial  resistance
should be  searched  for  (e.g.,  a  quinolone  resistance
gene),  as  they  often  coexist  on  the  same  plasmid.
Table 3  summarizes  the  detection  and  conﬁrmatory
tests.
When treating  with  a  patient  with  a high-
risk probability  of  carrying  a  carbapenem-resistant
organism,  it  is  recommended  to  screen  samples
from rectal  swabs,  tracheal  secretions  and  surgical
sites.  Organisms  demonstrating  decreased  break-
points should  be  conﬁrmed  by  one  of  the  above
tests.
Treatment
Limited  options  are  currently  available  to  treat
carbapenem-resistant  Enterobacteriaceae,  as  they
are resistant  to  all  -lactam  antibiotics  and  very
often carry  the  same  transposon  genes  responsi-
ble for  resistance  to  TMP-SMX,  aminoglycosides  and
ﬂuoroquinolones  [60].  Active  agents  include  tigecy-
cline, colistin  and  fosfomycin  [61].
Tigecycline  is  a  glycylcycline,  which  inhibit  pro-
tein translation  in  bacteria  by  binding  to  the  30S
ribosomal  subunit  and  blocking  the  entry  of  amino-
acyl tRNA  molecules  into  the  A  site  of  the  ribosome.
This prevents  the  incorporation  of  amino  acid
residues into  elongating  peptide  chains.  This  treat-
ment is indicated  for  the  skin,  soft  tissue  and  intra-
abdominal  infections.  Its  high  tissue  distribution
p
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nd  the  limited  clinical  experience  for  urinary  and
rimary bloodstream  infections  make  it  a poor  can-
idate for  treating  such  infections,  despite  high
n vitro  susceptibility  [62].  Reports  describing  the
se of  tigecycline  for  this  indication  have  ranged
rom failure  to  favorable  results  when  used  either
s a  monotherapy  or  in  combination  with  colistin
57,63];  the  major  side  effects  are  nausea,  vom-
ting, anaphylaxis/anaphylactoid  reactions,  acute
ancreatitis,  hepatic  cholestasis,  and  jaundice.
Colistin, or  colistimethate  sodium,  is  a  surface-
ctive agent  that  penetrates  into  and  disrupts  the
acterial cell  membrane.  It  has  been  shown  to  have
actericidal  activity  against  most  strains.  Though
eveloped  long  ago,  it  is  being  reused  in  desper-
te situations  in  the  era  of  antibiotic  resistance  to
reat infections  with  these  resistant  strains  [57,64].
t has  a  high  rate  of  success  when  used  in  combina-
ion therapy  but  not  as  a monotherapy.  However,
nterobacteriaceae  resistant  to  colistin  have  been
ecently described  [40].  The  concern  with  colistin  is
ts nephrotoxicity,  decreased  creatinine  clearance,
ncreased  urea,  respiratory  distress  and  apnea.
Fosfomycin  inhibits  bacterial  cell  wall
iogenesis by  inactivating  the  enzyme  UDP-N-
cetylglucosamine-3-enolpyruvyltransferase,  also
nown as  MurA.  This  enzyme  catalyzes  the  com-
itted  step  in  peptidoglycan  biosynthesis.  In  CLSI
011 [53],  it  is  indicated  for  use  against  E.  coli  UTI
solates only.  However,  a  recent  study  reported
xcellent in  vitro  activity  of  fosfomycin  against
. pneumoniae  strains  producing  KPC  resistant  to
ither colistin  and/or  tigecycline.  However,  no
linical correlation  was  found;  the  susceptibility
ates were  93%  for  the  overall  group,  87%  for
he tigecycline  and/or  colistin  non-susceptible
ubgroup,  and  83%  for  the  extremely  drug-resistant
ubgroup (tigecycline  and  colistin  non-susceptible
ubgroup) [65].  The  most  common  side  effects  are
iarrhea,  headache,  vaginitis,  nausea,  rhinitis,
ack  pain,  dysmenorrhea,  pharyngitis,  dizziness,
bdominal  pain,  anaphylaxis  and  hearing  loss.
Because of  the  above-noted  limitations  in  ther-
peutic  choices,  several  drugs  have  been  under
esearch and  development.  For  example,  the  newly
eveloped  drug  BAL30376,  which  is  a combina-
ion of  BAL19764  (a  metallo--lactamase  stable
onobactam),  BAL  29880  (bridged  monobactam
o inhibit  AmpC)  and  clavulanate  (inhibits  ESBLs),
as active  against  strains  producing  MBL  and
XA-48 but  demonstrated  poor  activity  against  KPC-
roducing Enterobacteriaceae  due  to  clavulanate’s
oor inhibitory  activity  against  these  enzymes  [66].
In a phase  II  trial  study,  NXL104  (a  -lactamase
nhibitor) in  combination  with  ceftazidime  or  aztre-
nam was  tested  against  carbapenem-resistant
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[he  threat  of  carbapenem-resistant  Enterobacteria
nterobacteriaceae.  Ceftazidime  +  NXL104  was
ctive against  strains  with  the  OXA-48  enzyme  or
ombinations  of  impermeability  and  an  ESBL  or
mpC enzyme  and  against  most  Klebsiella  spp.
ith the  KPC  enzyme,  but  it  was  not  effective
gainst metallo--lactamase  producers.  Aztre-
nam  +  NXL104  was  active  against  all  strains,
ncluding those  with  metallo--lactamases,  e.g.,
he NDM-1  gene  [67].
LK-157  is  a  novel  tricyclic  carbapenem  that  has
een shown  to  have  potent  activity  against  class  A
nd class  C  -lactamases,  indicating  the  need  for
urther development  [68].
The activity  of  BLI-489,  a  bicyclic  penem
olecule, was  tested  against  a  wide  variety  of
nzymes  but  still  must  be  assessed  against  KPC-
roducing  organisms  [69].
Lastly, ACHN-409,  a  new-generation  aminoglyco-
ide (neoglycoside),  is  currently  under  investigation
nd  appears  to  have  potent  in  vitro  activity  against
PC-producing  isolates  [70].
Due to  the  likely  spread  of  these  highly  life-
hreatening bacteria,  physicians  should  remain
ighly  suspicious  of  infections  with  these  resistant
rganisms  for  any  patient  presenting  from  endemic
reas.  Thus,  screening  suspected  patients  (e.g.,  by
ampling rectal,  tracheal,  and  wound  swabs)  is  war-
anted upon  admission  to  the  hospital.  Moreover,
rompt infection  control  measures  with  proper  con-
act isolation  should  be  implemented  until  the
nfection  or  colonization  with  these  highly  resistant
acteria  has  been  ruled  out.
onclusions
imilar  to  many  other  countries  worldwide,
ebanon and  its  neighboring  countries  are  now
acing  a  dangerous  threat  with  the  emergence
f carbapenem-resistant  Enterobacteriaceae.  The
urrently available  antibiotics  for  treatment  have
imited efﬁcacy.  There  are  few  potent  antimicrobial
gents with  activity  against  these  multidrug-
esistant bacteria;  there  are  very  few  agents  that
ave good  prospects.  A  multidisciplinary  approach
o limit  the  spread  of  these  organisms  is  essen-
ial. Acute  attention  and  a  high  degree  of  alertness
hould  be  maintained  when  facing  any  patient
ho has  been  in  areas  endemic  with  these  car-
apenemases,  such  as  the  Indian  subcontinent
nd recently,  Iraq.  Prompt  detection,  proper  pre-
ention,  antimicrobial  stewardship  and  adequate
nfection  control  measures  should  aid  in  limiting  the
pread of  these  organisms.
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